Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

October 12, 2027

Study Completion Date

October 10, 2028

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG

Chemotherapy/Radiation

Combination of radiation and chemotherapy

Trial Locations (1)

Juravinski Hospital, Hamilton

All Listed Sponsors

collaborator

McMaster University

OTHER

lead

Hamilton Health Sciences Corporation

OTHER